Shares Of Lupin
- All
- News
- Videos
-
Lupin's December Quarter Profit Declines 72% To Rs 153 Crore
Lupin had reported a net profit of Rs 545 crore for October-December period last fiscal.
-
Lupin Stock Up 4% On September Quarter Results
Shares of Lupin today climbed 4 per cent after the company reported a profit in the September quarter.
-
Lupin Gains Nearly 1% As Subsidiary Gets New Drug Approval
The USFDA approved Lupin's US-based arm's supplemental new drug application (sNDA) to expand the use of Solosec for treating trichomoniasis in adults, Lupin said
-
Stocks To Watch:Banking Shares, Mahindra & Mahindra, Lupin
The shares of PSU and private banks are likely to be in the limelight as the Reserve Bank of India will announce its monetary policy today
-
Stocks To Watch: Reliance Industries, PNB, Lupin Shares In Focus Today
Stocks In Focus Today: PNB raised over 54% of targeted fund mop-up through a qualified institutional placement (QIP) of shares
-
Dr Reddy's Soars To Record High After Drug Maker Settles Patent Litigation In US
The Nifty Pharma index - which captures the performance of 10 drug makers in the country, including Dr Reddy's, Lupin, Cipla and Sun Pharma - jumped as much as 3.66 per cent.
-
Buy Firstsource Solutions, Lupin Shares, Says Choice Broking
Choice Broking has a "buy" call on Firstsource Solutions for a target price of Rs 54.50 with stop loss at Rs 49.25.
-
Lupin Profit At Rs 266 Crore In September Quarter, Misses Analysts' Estimates
Net profit was 266 crore ($36.00 million) in the quarter ended September 30, compared with a profit of Rs 455 crore a year earlier, Lupin said.
-
Sensex, Nifty Turn Flat On Weak Global Cues
Stock markets on Monday: Wipro, Lupin, Tata Motors, Sun Pharma and Dr Reddy's led the pack of Nifty gainers.
-
Lupin Profit Falls 43% In June Quarter, Misses Analysts' Estimate
Sanctions imposed by international regulatory bodies and warnings over quality control at production sites have hurt sales in the United States where Indian pharmaceutical firms accounted for a third of the drugs sold.
-
Sensex Closes 30 Points Higher Despite Renewed US-China Trade War Fears: 10 Points
Indian stock markets managed to close marginally higher on Friday, despite fresh global trade war fears. The BSE Sensex finished 30 points higher at 33,626 while the NSE Nifty settled six points higher at 10,331. Some buying was witnessed in PSU pharma and energy stocks. Top gainers on the Nifty 50 were Aurobindo Pharma, Lupin and BPCL, closing wit...
-
Sensex Surges 286 Points, Nifty Settles Above 10,200; Auto, Pharma Stocks Lead Gains
The BSE Sensex started the first trading session of the new financial year on a positive note. The BSE benchmark index Sensex rose 286 points to close at 33,255, while the NSE Nifty settled 98 points higher at 10,211. Gains were led by buying witnessed across auto and pharma stocks, with the NSE's sectoral indices finishing the day 2-3 per cent hig...
-
Sensex Recovers From Intraday Lows, RIL, HDFC Bank Among Top Movers
From the Nifty basket of shares, 27 were trading higher while 24 were among the losers. Lupin was the top Nifty gainer, up 4.35 per cent at Rs 1,128 on value buying.
-
Sensex Flat, Nifty Struggles Around 9,600; Pharma Shares Gain
The Nifty Pharma sub-index of NSE was up 2.65 per cent. The pharma sub-index fell 8 per cent in May compared to 3.3 per cent gain in the broader Nifty.
-
Lupin's Market Value Falls By Nearly Rs 5,500 Crore In One Day. Here Is Why
North America sales at Lupin slumped 13 per cent in the fourth quarter, dragging down net profit to Rs 380 crore from Rs 748 crore a year earlier.
-
Lupin's December Quarter Profit Declines 72% To Rs 153 Crore
Lupin had reported a net profit of Rs 545 crore for October-December period last fiscal.
-
Lupin Stock Up 4% On September Quarter Results
Shares of Lupin today climbed 4 per cent after the company reported a profit in the September quarter.
-
Lupin Gains Nearly 1% As Subsidiary Gets New Drug Approval
The USFDA approved Lupin's US-based arm's supplemental new drug application (sNDA) to expand the use of Solosec for treating trichomoniasis in adults, Lupin said
-
Stocks To Watch:Banking Shares, Mahindra & Mahindra, Lupin
The shares of PSU and private banks are likely to be in the limelight as the Reserve Bank of India will announce its monetary policy today
-
Stocks To Watch: Reliance Industries, PNB, Lupin Shares In Focus Today
Stocks In Focus Today: PNB raised over 54% of targeted fund mop-up through a qualified institutional placement (QIP) of shares
-
Dr Reddy's Soars To Record High After Drug Maker Settles Patent Litigation In US
The Nifty Pharma index - which captures the performance of 10 drug makers in the country, including Dr Reddy's, Lupin, Cipla and Sun Pharma - jumped as much as 3.66 per cent.
-
Buy Firstsource Solutions, Lupin Shares, Says Choice Broking
Choice Broking has a "buy" call on Firstsource Solutions for a target price of Rs 54.50 with stop loss at Rs 49.25.
-
Lupin Profit At Rs 266 Crore In September Quarter, Misses Analysts' Estimates
Net profit was 266 crore ($36.00 million) in the quarter ended September 30, compared with a profit of Rs 455 crore a year earlier, Lupin said.
-
Sensex, Nifty Turn Flat On Weak Global Cues
Stock markets on Monday: Wipro, Lupin, Tata Motors, Sun Pharma and Dr Reddy's led the pack of Nifty gainers.
-
Lupin Profit Falls 43% In June Quarter, Misses Analysts' Estimate
Sanctions imposed by international regulatory bodies and warnings over quality control at production sites have hurt sales in the United States where Indian pharmaceutical firms accounted for a third of the drugs sold.
-
Sensex Closes 30 Points Higher Despite Renewed US-China Trade War Fears: 10 Points
Indian stock markets managed to close marginally higher on Friday, despite fresh global trade war fears. The BSE Sensex finished 30 points higher at 33,626 while the NSE Nifty settled six points higher at 10,331. Some buying was witnessed in PSU pharma and energy stocks. Top gainers on the Nifty 50 were Aurobindo Pharma, Lupin and BPCL, closing wit...
-
Sensex Surges 286 Points, Nifty Settles Above 10,200; Auto, Pharma Stocks Lead Gains
The BSE Sensex started the first trading session of the new financial year on a positive note. The BSE benchmark index Sensex rose 286 points to close at 33,255, while the NSE Nifty settled 98 points higher at 10,211. Gains were led by buying witnessed across auto and pharma stocks, with the NSE's sectoral indices finishing the day 2-3 per cent hig...
-
Sensex Recovers From Intraday Lows, RIL, HDFC Bank Among Top Movers
From the Nifty basket of shares, 27 were trading higher while 24 were among the losers. Lupin was the top Nifty gainer, up 4.35 per cent at Rs 1,128 on value buying.
-
Sensex Flat, Nifty Struggles Around 9,600; Pharma Shares Gain
The Nifty Pharma sub-index of NSE was up 2.65 per cent. The pharma sub-index fell 8 per cent in May compared to 3.3 per cent gain in the broader Nifty.
-
Lupin's Market Value Falls By Nearly Rs 5,500 Crore In One Day. Here Is Why
North America sales at Lupin slumped 13 per cent in the fourth quarter, dragging down net profit to Rs 380 crore from Rs 748 crore a year earlier.
